Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital.

Pocurull A, Moreta MJ, Heitman D, Olivas I, Collazos C, Canga E, SĂĄez-PeĂąataro J, Andrade RJ, Lucena MI, MariĂąo Z, DĂ­az A, Lens S, LondoĂąo MC, Forns X

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, LondoĂąo MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, FrĂźndt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, LondoĂąo MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, FrĂźndt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K

Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta-analysis.

Appenzeller-Herzog C, Rosat A, Mathes T, Baroja-Mazo A, Chruscinski A, Feng S, Herrero I, Londono MC, Mazariegos G, Ohe H, Pons JA, Sanchez-Fueyo A, Waki K, Vionnet J

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.

Murray SM, Pose E, Wittner M, LondoĂąo MC, Schaub G, Cook J, Dimitriadis S, Meacham G, Irwin S, Lim Z, Duengelhoef P, Sterneck M, Lohse AW, Perez V, Trivedi P, Bhandal K, Mullish BH, Manousou P, Provine NM, Avitabile E, Carroll M, Tipton T, Healy S, Burra P, Klenerman P, Dunachie S, Kronsteiner B, Maciola AK, Pasqual G, Hernandez-Gea V, Garcia-Pagan JC, Lampertico P, Iavarone M, Gines P, LĂźtgehetmann M, Schulze Zur Wiesch J, Russo FP, Barnes E, Marjot T, OCTAVE Collaborative Group, PITCH study, and the EASL supported COVID-Hep vaccine network

Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.

Martínez-Campreciós J, Riveiro-Barciela M, Muùoz-Gómez R, Londoùo MC, Roget M, Serra MÁ, Escudero-García D, Purchades L, Rodríguez M, Losa-García JE, GutiÊrrez ML, Carmona I, García-Samaniego J, Morano L, Martín-Granizo I, Montero-Alonso M, Prieto M, Delgado M, Ramos N, Azancot MA, Rodríguez-Frías F, Buti M

Development of a novel scoring tool to predict the need for early cricothyroidotomy in trauma patients.

LondoĂąo M, Nahmias J, Dolich M, Lekawa M, Kong A, Schubl S, Inaba K, Grigorian A

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner DE, De Martin E, Kullak-Ublick GA, Stirnimann G, Devarbhavi H, Vierling JM, Manns MP, Sebode M, LondoĂąo MC, Avigan M, Robles-Diaz M, GarcĂ­a-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi PJ, Hayashi PH, Taubert R, Fontana RJ, Weber S, Oo YH, Zen Y, Licata A, Lucena MI, Mieli-Vergani G, Vergani D, BjĂśrnsson ES, IAIHG and EASL DHILI Consortium

OprF Impacts Pseudomonas aeruginosa Biofilm Matrix eDNA Levels in a Nutrient-Dependent Manner.

Cassin EK, Araujo-Hernandez SA, Baughn DS, Londono MC, Rodriguez DQ, Al-Otaibi NS, Picard A, Bergeron JRC, Tseng BS

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.

Murillo Perez CF, Ioannou S, Hassanally I, Trivedi PJ, Corpechot C, van der Meer AJ, Lammers WJ, Battezzati PM, Lindor KD, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, ParĂŠs A, LondoĂąo MC, Janssen HLA, Invernizzi P, Vuppalanchi R, Hirschfield GM, Hansen BE, Levy C, Global PBC Study Group

Detection of M2-Type Anti-Mitochondrial Autoantibodies against Specific Subunits in the Diagnosis of Primary Biliary Cholangitis in Patients with Discordant Results.

Arnaldos-PÊrez C, PÊrez-Isidro A, Bolos U, Domènech C, Ballús J, Rodríguez-Tajes S, Londoùo MC, Viùas O, Ruiz-Ortiz E

Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.

Díaz-Gonzålez Á, Hernåndez-Guerra M, PÊrez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Díaz A, Gómez E, Morillas RM, Del Barrio M, EscudÊ L, Mateos B, Horta D, Gómez J, Conde I, Ferre-Aracil C, El Hajra I, Arencibía A, Zamora J, Fernåndez A, Salcedo M, Molina E, Soria A, EstÊvez P, López C, Álvarez-Navascúes C, García-Retortillo M, Crespo J, Londoùo MC, ColHai Registry

OprF impacts Pseudomonas aeruginosa biofilm matrix eDNA levels in a nutrient-dependent manner.

Cassin EK, Araujo-Hernandez SA, Baughn DS, Londono MC, Rodriguez DQ, Tseng BS

Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.

Riveiro-Barciela M, Barreira-Díaz A, Callejo-PÊrez A, Muùoz-Couselo E, Díaz-Mejía N, Díaz-Gonzålez Á, Londoùo MC, Salcedo MT, Buti M

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.

Lim TY, Perpiùån E, Londoùo MC, Miquel R, Ruiz P, Kurt AS, Kodela E, Cross AR, Berlin C, Hester J, Issa F, Douiri A, Volmer FH, Taubert R, Williams E, Demetris AJ, Lesniak A, Bensimon G, Lozano JJ, Martinez-Llordella M, Tree T, Sånchez-Fueyo A